Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

1.

alpha-Synuclein gene haplotypes are associated with Parkinson's disease.

Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M, West A, de Silva R, Hardy J, Hernandez D.

Hum Mol Genet. 2001 Aug 15;10(17):1847-51.

2.

Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes.

West AB, Zimprich A, Lockhart PJ, Farrer M, Singleton A, Holtom B, Lincoln S, Hofer A, Hill L, Müller-Myhsok B, Wszolek ZK, Hardy J, Gasser T.

Eur J Hum Genet. 2001 Sep;9(9):659-66.

3.

Complex relationship between Parkin mutations and Parkinson disease.

West A, Periquet M, Lincoln S, Lücking CB, Nicholl D, Bonifati V, Rawal N, Gasser T, Lohmann E, Deleuze JF, Maraganore D, Levey A, Wood N, Dürr A, Hardy J, Brice A, Farrer M; French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility on Parkinson's Disease.

Am J Med Genet. 2002 Jul 8;114(5):584-91. Erratum in: Am J Med Genet 2002 Dec 8;114(8):992.

PMID:
12116199
4.

Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations.

Wu RM, Shan DE, Sun CM, Liu RS, Hwu WL, Tai CH, Hussey J, West A, Gwinn-Hardy K, Hardy J, Chen J, Farrer M, Lincoln S.

Mov Disord. 2002 Jul;17(4):670-5.

PMID:
12210855
5.

Functional association of the parkin gene promoter with idiopathic Parkinson's disease.

West AB, Maraganore D, Crook J, Lesnick T, Lockhart PJ, Wilkes KM, Kapatos G, Hardy JA, Farrer MJ.

Hum Mol Genet. 2002 Oct 15;11(22):2787-92.

6.

Identification of a novel gene linked to parkin via a bi-directional promoter.

West AB, Lockhart PJ, O'Farell C, Farrer MJ.

J Mol Biol. 2003 Feb 7;326(1):11-9.

PMID:
12547187
7.

Parkin is not regulated by the unfolded protein response in human neuroblastoma cells.

West AB, Gonzalez-de-Chavez F, Wilkes K, O'Farrell C, Farrer MJ.

Neurosci Lett. 2003 May 1;341(2):139-42.

PMID:
12686385
8.

Parkin-proven disease: common founders but divergent phenotypes.

Lincoln S, Wiley J, Lynch T, Langston JW, Chen R, Lang A, Rogaeva E, Sa DS, Munhoz RP, Harris J, Marder K, Klein C, Bisceglio G, Hussey J, West A, Hulihan M, Hardy J, Farrer M.

Neurology. 2003 May 27;60(10):1605-10.

PMID:
12771249
9.

Genetics of parkin-linked disease.

West AB, Maidment NT.

Hum Genet. 2004 Mar;114(4):327-36. Epub 2004 Jan 15. Review.

PMID:
14727181
10.

N-myc regulates parkin expression.

West AB, Kapatos G, O'Farrell C, Gonzalez-de-Chavez F, Chiu K, Farrer MJ, Maidment NT.

J Biol Chem. 2004 Jul 9;279(28):28896-902. Epub 2004 Apr 12.

11.

Molecular pathophysiology of Parkinson's disease.

Moore DJ, West AB, Dawson VL, Dawson TM.

Annu Rev Neurosci. 2005;28:57-87. Review.

PMID:
16022590
12.

To die or grow: Parkinson's disease and cancer.

West AB, Dawson VL, Dawson TM.

Trends Neurosci. 2005 Jul;28(7):348-52. Review.

PMID:
15913799
13.

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7. Epub 2005 Nov 3.

14.

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.

Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18676-81. Epub 2005 Dec 13.

15.

Localization of LRRK2 to membranous and vesicular structures in mammalian brain.

Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL.

Ann Neurol. 2006 Nov;60(5):557-69.

PMID:
17120249
16.

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM.

Hum Mol Genet. 2007 Jan 15;16(2):223-32. Epub 2007 Jan 2.

17.

Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain.

Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RL, Waldvogel HJ, Arai H, Dawson TM, Moore DJ, Emson PC.

Brain Res. 2007 Jun 25;1155:208-19. Epub 2007 Apr 19.

PMID:
17512502
18.

Dynamic and redundant regulation of LRRK2 and LRRK1 expression.

Biskup S, Moore DJ, Rea A, Lorenz-Deperieux B, Coombes CE, Dawson VL, Dawson TM, West AB.

BMC Neurosci. 2007 Nov 28;8:102.

19.

Parkin mediates the degradation-independent ubiquitination of Hsp70.

Moore DJ, West AB, Dikeman DA, Dawson VL, Dawson TM.

J Neurochem. 2008 Jun;105(5):1806-19. doi: 10.1111/j.1471-4159.2008.05261.x. Epub 2008 Feb 1.

PMID:
18248624
20.

The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Sen S, West AB.

Antioxid Redox Signal. 2009 Sep;11(9):2167-87. doi: 10.1089/ARS.2009.2430.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk